PRE-CONGRESS WORKSHOPS
APRIL 21-24, 2025
WALTER E. WASHINGTON CONVENTION CENTER, WASHINGTON D.C.
World Vaccine Congress Washington 2025's highly anticipated pre-congress workshops are back!
Designed for in-depth discussions and insights into vaccine progress, our workshops on April 21, 2025, cover various domains, including new vaccine technology, biodefense, antimicrobial resistance, global health, alternative vaccine targets, and vaccine delivery.
Join our pre-congress workshops on April 21, 2025.
Reserve your seat today with our discount ticket package ,which grants you access to: Workshops (April 21, 2025) (a full-day workshop or the flexibility to choose one morning workshop and one afternoon workshop), Conference Sessions (April 22-24, 2025) and Exhibition (April 22-24, 2025)
FULL-DAY WORKSHOPS - 10:00 to 17:00
[W1] BIODEFENSE:
Protecting public health from biothreats to pandemics + International funding & collaboration
What is the progress on new technologies in medical product development? How our governments are incentivizing (portfolio approach), especially with biotech and industry? What international collaborations are being facilitated?
Agenda :
- Workshop leader opening remarks
- Coupled lightening talks: How our governments are incentivizing (portfolio approach), especially with biotech and industry?
-
Partnering with the private sector - how to raise capital for your next gen vaccine?
- Securing private funding for outbreaks and threats
- Rapid vaccine development through manufacturing innovation
- 1:00 - 2:00 pm: Networking break
- What are the remaining bottlenecks holding us back from achieving the 100-day mission?
- An international pandemic fund - how can we make it accessible globally?
Workshop Speakers:
- Dr Chris Earnhart , Chief Technology Officer, JPEO-CBRND Enabling Biotechnologies (JPEO-CBRND-EB)
- Cristina Cassetti, Deputy Director, Division of Microbiology and Infectious Diseases, NIAID, NIH
- Kelly Warfield , Sabin Vaccine Institute’s President of Research & Development, Sabin Institute
- Nicole Dorsey , M CIV USARMY DOD, JPEO CBRND (USA)
- Luciana Borio, Venture Partner, ArchVentures
- Hamilton Bennett, Senior Director, Vaccine Access and Partnerships, Moderna
- Bassam Hallis, Deputy Director, Vaccine Development and Evaluation Centre, UKHSA
- Dr Seth Berkley, Former CEO, Gavi ; Senior Advisor, Pandemic Center at Brown University
- Dr Christian Tientcha Happi, Professor of Molecular Biology and Genomics in the Department of Biological Sciences and Director, African Center of Excellence for Genomics of Infectious Diseases (ACEGID)
- Santiago Cornejo, Executive Director, Regional Revolving Fund, PAHO
- Mike Stebbins, Manufacturing and Threat Countermeasures Division, ATI
- Renee Hart, President and CBO, LumaCyte
-
Dave Bailey , CIV USARMY DOD JPEO CBRND (USA)
-
Lakshmi Krishnan , Vice President of Research, National Research Council of Canada
-
Dr Philip Krause , Former FDA & WHO Advisor
-
Marion Gruber , Vice President, Public Health and Regulatory Affairs, IAVI
-
Ritu Banerjee , Assistant Deputy Minister, Office of Life Sciences and Biomanufacturing Readiness at Innovation, Science and Economic Development Canada
More to be announced...
[W2] ANTIMICROBIAL RESISTANCE
:
Pipeline updates for priority bacterial pathogens & evaluating the impact of vaccines against AMR
Agenda:
- Pipeline Updates for Priority Pathogens
- Shigella and Salmonella
- Acinetobacter
- Group B streptococcus
- Staph Aureus & MRSA
- Klebsiella
- Panel: Commonalities and challenges for advancing the development of vaccines against priority AMR pathogens
- Development and impact of novel TB vaccines
- Development of 24-valent Pneumococcal Conjugate Vaccine and measuring impact on AMR
- Measuring the impact of vaccines on antimicrobial resistance
- 1:00 - 2:00 pm: Networking break
- Tackling AMR: An overview of the BMGF Strategy
- Funding and Partnering to support novel tools against AMR
Workshop Speakers:
- Francesca Micoli, Director, GVGH Innovation Academy & Senior Project Leader, GSK
- Prof. Luigi Lay, Department of Chemistry, University of Milan
- Dr Michael Kowarik, CSO, Limmatech
- Prof. Xufei Huang, Associate Chair for Research, Chemistry and Biomedical Engineering, Michigan State University
- Tim Cooke, CEO, Omniose
- Dr Christian Harding, CSO and Co-founder , Omniose
- Dr Lewis Schrager , Senior Leader, TB Impact Area, IAVI
- Megan Carey , Associate director – AMR Strategy Unit, IAVI
- Dr Usman Nakakana , Senior Program Officer for Clinical Vaccine Development, Bill & Melinda Gates Foundation
- Jim Wassil , COO, Vaxcyte
- Dr Vega Masigani , Alliance Director, CARB-X
- Dr Alexander Schmidt , Head of Vaccine Development, Bill & Melinda Gates Medical Research Institute
-
Dr Arman Majidulla , Assistant Scientist, Johns Hopkins Bloomberg School of Public Health
-
Dr Mukadi YaDiul , Deputy Division Chief, TB Division, USAID
-
Dr Birgitte Giersing , Team Lead, Vaccine Prioritization, WHO
-
Douglas Thomson , Venture Partner, Kineticos AMR Accelerator Fund (KAMRA)
-
Cho Pharma
-
Bactivac Board Member
More to be announced...
[W3] OPTIMIZING mAbs FOR INFECTIOUS DISEASES:
developing improved antibody-based therapies for infectious disease
Agenda:
- Workshop leader’s opening remarks
- Strategies to optimize mAbs for malaria
- Development of mAbs for unmet needs in global health
- Computationally restoring the potency of clinical antibodies
- Antibody engineering for ID (in vivo expression)
- Developing Ab therapies that keep pace with rapidly evolving viral threats (COVID + Flu)
- dmAb platform
- Commercialisation challenges for mAb products – understanding pathways to recommendation
-
Global barriers to access for ID mAbs – from manufacture to delivery
-
Taking mAbs to the next level: Recombinant polyclonal antibody therapeutics
Workshop Speakers:
- Dr Neville Kisalu, Program Advisor: Vaccine Immunologist, PATH’s Center for Vaccine Innovation and Access
- Dr Larry Zeitlin, President, Mapp Biopharma
- Dr Robert Allen , CSO, Invivyd
- Dr Daniel Faissol, Principal Investigator, Center for Bioengineering, Executive Director, Predictive Design of Biologics, LLNL
- Richard Hughes, Partner, Epstein Becker and Green; Professor of Law, The George Washington University Law School
-
Dr Dave Liebowitz , Senior Vice President, Early-Stage Clinical Development, Inovio
-
Dr Giuseppe Sautto , Assistant Professor, Cleveland Clinic
-
Jonathan Heeney , CSO, DIOSynVax
-
Sheila Keating , VP Immunology, Grifols
-
Dr Fadil Bidmos , UK MRC Senior (Non-Clinical) Fellow, Imperial College London
More to be announced...
MORNING WORKSHOPS - 10:00 to 13:00
[AM1]
VACCINE TECHNOLOGY:
Cutting-edge technologies shaping the future of vaccine development
Cutting-edge technologies shaping the future of vaccine development.
Agenda:
- Vaccine technology platforms
- Innovating Vaccine Development: The Role of VaxArray in SolaVAX, a novel photochemical inactivation vaccine platform*Title TBC
- Intranasal, Clinical-stage W805EC Adjuvant: Safety and Immunogenicity
- Epitope Disk Nanoparticle, a Disease Agnostic Vaccine Platform
- Panel - The Evolving Landscape of Novel Adjuvant Development - Navigating Safety, Access and Innovation
Workshop Speakers:
- Dr Chad Costley , CEO & President, Blue Willow Biologics
- Kristyn Aalto , CEO, Orlance
- Dr Wian de Jongh , CEO, AdaptVac
- Dr Wolfgang Leitner, Chief, Innate Immunity Section, NIH
- Derek O'Hagan, Senior Advisor R&D, GSK
- Dr Sheetij Dutta , Chief Laboratory of Structural Vaccinology, Walter Reid Army Institute of Research
- Dr Jay Evans , Chief Scientific and Strategy Officer, Inimmune & Director of the Center for Translational Medicine at the University of Montana
-
Dr Aurelio Bonavia , Vaccine/Monoclonal Antibody Development, Bill & Melinda Gates Medical Research Institute
-
Dr Roland Ventura , VFI Senior Advisor for Strategy, Vaccine Formulation Institute
- Senior Representative, InDevR
- Senior Representative, Amerstem
- Senior Representative, Advanced Access Health Initiative
More to be announced...
[AM3] ALTERNATIVE VACCINE TARGETS:
Exploring the development of vaccines against non-infectious disease targets
Exploring the development of vaccines against non-infectious disease targets.
Agenda:
- Chair opening remarks
-
Clinical development of vaccines for opioid overdose and allergy
-
Advancing a vaccine targeting C9orf72 ALS to the clinical stage
-
Adjuvant centric development of overdose preventing vaccines targeting fentanyl
-
Development of adjuvanted vaccines for allergy and Alzheimer’s and drug addiction* title TBC
-
The potential impact, feasibility and progress in clinical development of senotherapeutics
-
What are the unique challenges of getting non-traditional target vaccines to market?
Workshop Speakers:
- Jay Evans, InImmune, University of Montana
- Dr Robert van der Put , Director Business Development, Intravacc
-
Dr David Dowling , Assistant Professor of Pediatrics, Harvard Medical School
-
Dr. Shon Remich , MD, and CMO, Ovax
-
Dr Nikolai Petrovsky , Chairman, Vaxine Pty Ltd.
More to be announced...
[AM4] COMBINATION VACCINES:
Considerations from bench to bedside for novel combination vaccines
Agenda:
- Implications for immunization programs
- Developing a WHO framework for novel combination vaccines
- Combination Vaccines: design and development
- Formulation and manufacturing complexities for combination vaccines
- A platform for combination vaccines
- Understanding demand and market opportunity for combination vaccines?
- Panel - Policy and regulatory opportunities and for the future of adult combination vaccines
Workshop Speakers:
- Dr William Hausdorff, Public Health Value Proposition Lead, PATH
- Dr Peter Hotez, Professor, Baylor College of Medicine & Co-Director, Texas Children's Hospital
- Dr Peter Dull , Integrated Clinical Vaccine Development, Global Health, Bill and Melinda Gates Foundation
- David Kaslow, Director, Office of Vaccines Research and Review (OVRR), CBER, FDA
- Dr Kayvon Modjarrad, Executive Director, Viral Vaccines, Vaccine Research and Development, Pfizer
- Dr Francesco Berlanda Scorza, VP, GLobal Health R&D Vaccines Head and GVGH Institute, GSK
- Birgitte Giersing, Team Lead, Vaccine Prioritization, WHO
- Dr Robert Sitrin , Senior Scientist Process Development, PATH
- Dr Tim Hirst , CEO, GPN Vaccines
- Dr Hanna Nohynek , Chief Physician, Deputy Head, Unit Infectious Diseases Control and Vaccines, Department Health Security, Finnish Institute for Health and Welfare, Chair, WHO SAGE
- Senior Representative, AstraZeneca
More to be announced...
AFTERNOON WORKSHOPS - 14:00 to 17:00
[PM1]
VACCINE DELIVERY:
Advanced vaccine delivery methods: novel routes and technologies to optimize administration, efficacy, and accessibility
Advanced vaccine delivery methods: novel routes and technologies to optimize administration, efficacy, and accessibility.
Agenda:
- Workshop Leader Opening Remarks
- Formulate the future: cutting-edge technologies for manufacturing of sustainable components of vaccine delivery systems
- The New Access Paradigm: Jump Starting Local Manufacturing & Community Delivery for Global Health Markets
- RNA & MAP - Combining breakthrough innovations
- Update on Vaxxas Microarray Patch Technology
- Chair's closing remarks
Workshop Speakers:
- Dr Dennis Christensen, Head of Global Research and Development, Adjuvant Systems, Croda
- Dr Irnela Bajrovic, Chief Scientific Officer, Jurata Thin Film
- Dr Edward Kelley, Chief Global Health Officer, Apiject
- Dr May Pidding , Director, Microneedle Array Patch Product Management, LTS Lohmann
- Dr Rochelle Chaiken , Chief Medical Officer, Vaxxas
- Lisa Purcell , Entrepreneur-In-Residence, Third Rock Ventures
More to be announced...
[PM2]
GLOBAL HEALTH VACCINES:
NTD and parasitic disease vaccines
Identifying innovative and collaborative solutions throughout the development pathway to advance NTD vaccine candidates beyond historical roadblocks.
Agenda:
- Workshop Leader Opening Remarks
-
Short talks on updates in development of vaccines for NTD vaccines
-
Hookworm anaemia and malaria combination vaccine
-
Early development of a vaccine against visceral leishmaniasis
-
A defined molecular vaccine for intestinal schistosomiasis
-
Development of vaccines for lymphatic filariasis
-
- Panel - Challenges in establishing correlates of protection and planning trials for NTD (parasitic) vaccines
- Panel - Moving the needle: alternative pathways to approval for parasitic and other NTD vaccines
Workshop Speakers:
- Dr Peter Hotez, Co-Director, Texas Children's Hospital Center for Vaccine Development, Baylor College
- Darrick Carter , CEO, PAI Lifesciences
- Maria Elena Bottazzi, Co-Director of Texas Children's Hospiral for Vaccine Development, Baylor College
- Dr Angamuthu Selvapandiyan, Professor, Departnment of Molecular Medicine School of Interdisciplinary Studies and Technology, JAMIA HAMDARD
- Afzal Siddiqui , Professor, Department of Internal Medicine, Professor (Tenured), Departments of Internal Medicine and Immunology & Molecular Immunology, Texas Tech University Health Sciences Center
- Dr Ramaswamy Kalyanasundaram , Department Head, Professor of Microbiology and Immunology, University of Illinois College of Medicine
- Javier Guzman , Director of Global Health Policy and Senior Fellow, Center for Global Development
- Petro Terblanche , Managing Director, Afrigen
- Prof Tuck Seng Wong , Professor, Sheffield University; Director, UKSEA Vax Hub
-
Dr Kelly Warfield , President of Global Research, Sabin Vaccine Institute
-
Dr William Hausdorff , Public Health Value Proposition Lead, PATH
More to be announced...
[PM3] HPV ELIMINATION:
What will it take to reach the 2030 HPV elimination goal?
Achieving Cervical Cancer Elimination through Prevention: Headwinds and Tailwinds
HPV-related cancers are preventable, yet the most effective evidence-based intervention to prevent and eliminate the disease, vaccination faces escalating opposition and misinformation, and an erosion of public trust, jeopardizing the critical progress toward achieving Cervical Cancer Elimination by 2030. At the same time, recent approvals of new self-sampling technology has the promise to help diagnose illness sooner and prompt early intervention. This session will bring together public health, cancer prevention, immunization, screening, and patient advocacy experts and leaders in the U.S. to discuss strategies for safeguarding HPV-cancer prevention efforts, while exploring policy solutions, breakthrough research, and cross-sector collaboration. Panelists will address the urgent need to protect current progress and accelerate and intensify efforts toward eliminating HPV-related cancers, starting with Cervical Cancer. The session will culminate in an interactive strategy session where participants will develop a Top 10 Essential Actions framework—a consensus-driven roadmap to achieve the goals of Cervical Cancer Elimination.
Agenda:
To be announced...
Workshop Speakers:
Hosted by Merck
- Kate Mevish , Merck
- Catherine Peters , Strategic Director, State & Local Campaigns - Access to Care, ACSCAN
- Erin Abramsohn , Executive Director, Infectious Disease Prevention Network
- Fenan Solomon , Director, Market Access & Payment Policy, Diagnostic Solutions and Specimen Management, Public Affairs, BD
[PM4]
RSV:
Addressing the impact of RSV on infants
Maximizing Protection: Enhancing National RSV Infant Immunization Strategies
The completion of two seasons of RSV immunization for infants provides us with an opportunity to reflect on ways to enhance policies, programs, and systems to maximize protection for infants. Successful national implementation of an RSV infant immunization program hinges on a coordinated, multi-faceted approach that includes raising awareness, enhancing provider education, ensuring accessibility, and fostering collaboration across various sectors. While we have made progress, there are opportunities to close remaining gaps. This panel will provide perspectives across policy, patient advocacy, and implementation to identify best practices to drive public health impact with these new strategies even as new preventive options become available.
Agenda:
To be announced...
Workshop Speakers:
To be announced...
[PM5]
DRIVING KOREA'S VACCINE R&D CAPABILITIES TOWARDS REGIONAL AND GLOBAL PUBLIC HEALTH:
Exploring Korea’s impact on the global and local vaccine ecosystem
This workshop will be split into two sections, starting with Korea’s Efforts to Contribute to Regional and Global Vaccine R&D, followed by International Partnerships for Vaccine Equity. Join this workshop to meet speakers not only from South Korea, but also from other international Asian markets that are driving vaccine R&D and manufacturing capacity.
Agenda:
- Korea's efforts to contribute to regional and global vaccine R&D
- Panel Discussion with the Korean government and industry on current and future international partnerships in vaccine R&D and local manufacturing
- International Partnerships for Vaccine Equity Panel: collaboration between Korean and international partners to support regional and global health through partnership in R&D and establishment of local manufacturing of vaccine in LMICs
- Panel - What does it take to collaborate for impact on global vaccine equity? What are some best practices of effort for vaccine R&D and local manufacturing in LMICs?
Workshop Speakers:
- Kee Jong Hong , Project Manager , KHIDI
- Hyun Joo Yang , Director , GTH-B (Global Training Hub for Biomanufacturing) Foundation
- Hani Kim , Executive Director, Research Investment in Global Health Technologies Foundation, RIGHT Foundation , South Korea senior representative, GTH-B
- Gyoonhee Han , Professor , K-NIBRT
- Minsang Eom , Team Leader , LG Chem
- Hyesun Jun , Director of BD , QuadMedicin
- Dal-Hee Min , CTO , Lemonex
- Jerome Kim , Director General , IVI
- Nakorn Premsri , Director , Thailand NVI
- Soleh Ayubi , Deputy CEO , Bio Farma
- Raman Rao , CEO , Hileman laboratory
- Seok kyu Kim , Director , Eubiologics
More to be announced...
[PM6]
MPOX - BAVARIAN NORDIC:
Tools & strategies to combat Mpox
The Global Mpox Response: Epidemiology, Prevention, and Future Strategies
Agenda:
- Part I : Epidemiology & Mpox in Non-Endemic Countries
- Global Mpox Epidemiology: Trends, Insights and Emerging Challenges
- The Response to the 2022 Mpox Outbreak in Non-Endemic Countries
- Panel Discussion: Mpox in NON-Endemic Countries
- Part II : Mpox Response in Endemic Countries
- Strengthening Prevention in Endemic Regions: Lessons From the Ground
- The Role of MVA-BN in Mpox Management: Current Data and Future Directions
- Coordinating the Global Mpox Response Across Different Stakeholders: What Can We Learn From It?
- Panel Discussion
Workshop Speakers :
- Dr Boghuma K.Titanj , Assistant Professor of Medicine, Division of Infectious Diseases , Emory University School of Medicine
- Dr Hypolite Muhindo Mavoko , Professor, Department of Tropical Medicine , University of Kinshasa, DRC
- Dr Bernard Hoet , Vice President of Medical Affairs, Bavarian Nordic
- Dr Rosamund Lewis , Head, Smallpox Secretariat, Technical Lead for Orthopoxviruses, WHO
More to be announced...
[PM7]
IVI & WHO iNTS FVVA (Full Value of Vaccine Assessment) Meeting
Agenda :
- Welcome and opening remarks, context for and objectives of the meeting
- Part I: Invasive Non-Typhoidal Salmonella (iNTS)
- Microbiology and Disease Burden of Non-Typhoidal Salmonella
- The latest epidemiology and disease burden data of iNTS disease in infants (< 6 months) in sub-Saharan Africa
- WHO Preferred Product Characteristics (PPC) and Roadmap for iNTS-containing Vaccines
- Q&A discussion
- Part II: iNTS-Containing Vaccines
- iNTS-containing vaccine pipeline
- Safety and immunogenicity of the Trivalent Salmonella Conjugate Vaccine (TSCV)
- GMMA-based vaccines against iNTS disease
- Clinical and Regulatory Pathways for iNTS-containing vaccines
- Q&A discussion
- Part III: Full Value of Vaccine Assessment (FVVA)
- FVVA Overview and Activities
- Economic evaluation of a hypothetical iNTS vaccine
- Broader societal impacts of iNTS vaccines
- iNTS + TCV business case
- Summary and Panel Discussions
Workshop Speakers:
- Rob Kaminski , Consultant, World Health Organization
- Mike Levine , Associate Dean for Global Health, Vaccinology & Infectious Diseases, Center for Vaccine Development of the University of Maryland School of Medicine
- Hyonjin Jeon , Research Management Consultant, International Vaccine Institute, University of Cambridge
- Tarun Saluja , Head of Clinical Development, International Vaccine Institute
- Jerome Kim , Director General, International Vaccine Institute
- Wilbur Chen , Professor, Center for Vaccine Development of the University of Maryland School of Medicine
- Jung Seok Lee , Head of Policy and Economic Research Department, International Vaccine Institute
- Annelies Wilder-Smith , Team Lead, Department of Immunization, Vaccines & Biologicals (IVB), WHO (World Health Organization)
- Simon Procter , Assistant Professor, The London School of Hygiene & Tropical Medicine
- Nicole Revie , Senior Consultant, Shift Health
More to be announced...
M4] RSV: Addressing the impact of RSV on infants
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events